Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- COPD exacerbation
- Respiratory viruses and exacerbation
- Changes in bacterial load
- Exacerbation and bacterial strain change
- Lung microbiome
- Bacteria importance in exacerbation
- Factors that affect treatment
- Oral steroids at COPD exacerbation
- Sputum IL1-beta at bacterial exacerbation
- IP-10a ROC curve analysis
- Virus induce airway inflammation mechanism
- IFN-gamma mRNA and protein deficiency
- Experimental infection interferon production
- Exacerbation recovery
- Fatigue association with COPD exacerbation
- Exacerbation frequency and exercise capacity
- Pulmonary rehabilitation program
- Early pulmonary rehabilitation
- Reduction in exacerbation triggers
- Pollution and COPD exacerbation
- Significance of treatment delay and recovery time
- Symptom onset and early start of therapy
- Exacerbation clustering
- Importance of exacerbation
- Susceptibility to exacerbation
- Association of disease severity with exacerbations
- Factors associated with exacerbation frequency
- The NICE algorithm
- Poet study- salmeterol vs. tiotropium
- Indacaterol
- Rate of moderate and severe exacerbation
- Torch study: analysis by disease severity
- Uplift mild* COPD subgroup: exacerbations
- Inspire study
- Time to first exacerbation
- Roflumilast
- The effect of roflumilast on exacerbations
- Roflumilast significantly reduce exacerbation rate
- Rationale for macrolide use in COPD
- Macrolides - time to first exacerbation
- Symptom duration is responsive to therapy
- Macrolides - sputum markers
- Macrolides (azithromycin) study
- Macrolides study data analysis
- Long term antibiotics
- Bacterial load and airway inflammation
- Sub-group analysis
- Relation of comorbidity to COPD exacerbation
- Beta blockers treatment
- Non-pharmacological interventions
- Optimal care new perspective
Topics Covered
- Definition of exacerbations
- Breakdown of virus directed exacerbations
- Pollution and COPD
- Importance of exacerbations
- Eclipse study
- Poet study
- Torch study
- Inspire study
- Antibiotic use in COPD patients
- Non-pharmacological interventions
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Wedzicha, W. (2012, September 10). Mechanisms of COPD exacerbations and relation to exacerbation therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 14, 2024, from https://doi.org/10.69645/PBRD8172.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Wisia Wedzicha has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Hide